

**Evolution of tolbutamide in the treatment of diabetes mellitus**

Roshan Kumar<sup>1</sup>, Purabi Saha<sup>2\*</sup>, Priyatosh Pathak<sup>3</sup>, Ramayani Mukherjee<sup>4</sup>,  
Abhishek Kumar<sup>6</sup>, Rakesh Kumar Arya<sup>5</sup>.

1. SBS College of Pharmacy, Patti, Punjab, India.
2. Uttranchal University, Dehradun, Uttrakhand, India.
3. Bengal School of Technology, West Bengal, India.
4. Nshn Knowledge Campus Kolkata, West Bengal, India.
5. Indian Insititute of Technology Patna, Bihar, India.
6. Brilliant Science Coaching, Patna122, Bihar, India.

**Refer This Article**

Roshan Kumar, Purabi Saha, Priyatosh Pathak, Ramayani Mukherjee, Abhishek Kumar, Rakesh Kumar Arya , 2020. Evolution of tolbutamide in the treatment of diabetes mellitus . Journal of medical pharmaceutical and allied sciences, V 9 - I 6, Pages - 2605 – 2609.

Doi: <https://doi.org/10.22270/jmpas.V9I6.959>.

**Purabi Saha\***

Dept. of Pharmacy, Uttaranchal  
University, Dehradun, Uttrakhand, India  
✉ [purabisaha2000@gmail.com](mailto:purabisaha2000@gmail.com)

**Keywords**

Diabetes Mellitus, sulfonylureas,  
ATP-sensitive K<sup>+</sup> channels

**Received**

03/09/2020

**Reviewed**

08/09/2020

**Revised**

&

**Accepted**

02/10/2020

**ABSTRACT**

Diabetes Mellitus is becoming fast growing epidemic all over the world. Despite several oral drugs available in the market, the most traditional as well as the most popular of them all are tolbutamide. tolbutamides have been a foundation for maintaining glucose levels in type II diabetes. Although having many side effects, this class of compounds is still being used as the second-line recommended choice of oral glucose-lowering treatment after metformin. In the present review, various stages involved in the development of these drugs have been discussed through important case studies. The mode of action of tolbutamide in biological system has been reviewed. Comparison of commercially available tolbutamide has been made while discussing their chemical synthesis and metabolism inside gastrointestinal tract.

**INTRODUCTION**

Anti-diabetic medication treats polygenic disorder mellitus by lowering aldohexose levels in the blood. With the exceptions of endocrine, exenatide, and pramlintide, all area unit administered orally and area unit therefore additionally known as oral hypoglycaemic agents or oral antihyperglycemic agents. Sulfonylureas were discovered by the chemist Marcel Janbon and colleagues,<sup>(1)</sup> United Nations agency were finding out sulfa antibiotics and discovered that the compound antidiabetic drug elicited symptom in animals. analysis has shown the Maitake mushroom (*Grifola frondosa*) encompasses a hypoglycaemic impact, and should be useful for the management of polygenic disorder. the rationale Maitake lowers blood glucoseis due to the truth the mushroom naturally acts as Associate in Nursinging alpha glucosidase substance.<sup>(2)</sup>

Alternative mushrooms like Reishi, fungus genus blazei, Agro cybe cylinderacea and Cordyceps are reported to lower blood glucose levels to a particular extent, though the mechanism is presently unknown Walnut leaf will considerably scale back fast glucose levels in rats with alloxan-induced polygenic disorder, and rats therefore treat show some proof of regeneration of the beta cells. Garlic additionally considerably

reduces fast glucose levels in rats with alloxan-induced polygenic disorder.<sup>(3)</sup> Diabetes Mellitus is related to symptom (abnormal increase in blood glucose) ensuing from defects in endocrine secretion, endocrine action, or both Since many unhealthful processes are concerned within the development of polygenic disorder, the diabetic condition could end in semi-permanent injury, disfunction, or perhaps failure of assorted organs like kidneys, Declining duct gland duct gland operate has been considered a serious issue related to progressive rising of plasma aldohexose levels and malady progression in step with Belfast polygenic disorder Study and uk Prospective polygenic disorder Studies UKPDS. In each studies, extrapolation of information suggests that initial deterioration within the isle operate could occur up to fifteen years before designation of the malady.<sup>(4)</sup>

**History behind the invention of sulfonylurea**

The hypoglycemic impact of the sulfonylurea was initial discovered in France throughout war II. it had been rather good luck occurred throughout the course of investigations of antibiotic properties of changed sulfonylurea.




Figure: 1 Tolbutamide

Not abundant clinical application of those medication came into image till the synthesis of carbutamide once the war, in Germany, followed by the event of the agents known as sulfonylurea and chlorpropamide that were ordinarily employed in the u.s.<sup>(5)</sup> However, a black eye came once the University cluster polygenic disorder Program (UGDP), designed a 12-center prospective trial to match the efficaciousness of oral hypoglycaemic treatment (Tolbutamide) with UGDP reported that the patients taking sulfonylurea have accrued risk for vas mortality.<sup>(6)</sup>

Thereafter, many controversies were raised against the utilization of sulfonylureas however by the late Nineteen Seventies, use of those medication another time accrued, may be as a result of within the recent years, the effortful & intensive researches worldwide have upgraded these initial generation sulfonylureas to the second and therefore the third generation of compounds, that area unit way more potent than initial compounds<sup>(7)</sup> (Table 1).

### Mode of action of sulfonylurea

Once the sulfonylurea had taken hold over the market in spite of assorted associated controversies, scientists had wanted to work out the mechanism of their anti-hyperglycemic action. Initially, it had been thought that a rise in endocrine unleash is that the primary action however in early Nineteen Seventies, a heavy concern relating to the endocrine humour numerous tries had been created to develop a basis for understanding of assorted aspects which could be enjoying vital roles within the therapeutic action of those medication<sup>(8)</sup>


Finally in Nineteen Nineties, the mechanism of action of this category of compounds was found to be connected with nucleotide (ATP) sensitive atomic number 19 (K) channels. Structure and performance of adenosine triphosphate sensitive K channels (KATP): aldohexose level in blood stream is maintained by endocrine secretion from duct gland duct gland cells. The aldohexose metabolism in duct gland duct gland cells is that the crucial step in glucose-induced endocrine secretion. duct gland duct gland cells area unit electrically excitable cells, and aldohexose regulates endocrine secretion by dominant K permeable ness, that determines membrane potential.<sup>(9)</sup> Thus, the K

permeable ness of the  $\beta$ -cells could be a vital determinant of glucose-induced endocrine unleash. KATP channels were discovered originally in heart, and were later found in several alternative tissues together with duct gland duct gland cells, muscle, swish muscle before the identification of KATP channels in duct gland duct gland cells, however, the molecule linking aldohexose metabolism and membrane potential wasn't celebrated. KATP channel because the name suggests, could be a variety of atomic number 19 channel that's gated by adenosine triphosphate.<sup>(6)</sup> ATP-sensitive atomic number 19 channels area unit composed of eight super molecule subunits (octamer).<sup>(10-11)</sup>

Four of those area unit members of the Inward-Rectifier atomic number 19 particle channel family Kir6.x (either Kir6.1 or Kir6.2), whereas the opposite four area unit anti-diabetic drug Receptors (SUR). Kir6.2 will operate only it's co expressed with the port fractional monetary unit and is chargeable for K1 electrical phenomenon.<sup>(12)</sup> The port subunits have 3 extra trans membrane domains, and contain 2 nucleotide-binding domains on the protoplasm facet. These permit ester mediate regulation of the atomic number 19 channel. This unit acts as a detector of metabolic standing. These port subunits also are sensitive to sulfonylureas, Mg ATP, and a few alternative pharmacologic channel openers.<sup>(13)</sup>

In exocrine gland exocrine gland cells, since these channels square measure nucleotide gated channels; the ATP/ADP quantitative relation determines KATP channel activity. Underneath traditional conditions, the KATP channels in exocrine gland exocrine gland cells square measure impromptu active, permitting K ions to emanate the cell. However as before long as there's increase in aldohexose level resulting in inflated aldohexose metabolism, the KATP channels shut.<sup>(14-15)</sup>


This is often attributable to insurant inflated levels of nucleotide inflicting the membrane potential of the cell to depolarise, therefore promoting endocrine unharness. The change and polarization of channels happens quickly and synchronously.<sup>(16)</sup> Anti-diabetic medication has high affinity to bind with a Tyre monetary unit of the KATP channel. Thus, the deed of this receptor by a anti-diabetic drug inhibits flux of K through the channel pore resulting in change of the plasma lemma and therefore causing unharness of However, it ought to be recognized that the extra particle channels may additionally be targeted by anti-diabetic medication.<sup>(17)</sup>




**Figure:2- Mechanism of endocrine secretion from duct gland duct gland and internal secretion unleash from ucells. The theme shows the response of duct gland duct gland duct gland in response to high glucose. Endocrine secretion is initiated by aldohexose uptake and promoting action potentials leading to Ca<sup>2+</sup> inflow and endocrine secretion. GLP-1 augments endocrine secretion by activation of the GLP-1 receptor and obstruction of the KATP channel via the effector super molecules protein enzyme A (PKA) and therefore the cAMP-regulated purine ester exchange issue Epac. High glucose concentrations block {the unleash|the discharge} of internal secretion by initiating a membrane change and inactivation of the metal + channels what hampers Ca<sup>2+</sup> inflow and thereby internal secretion release.**

**Commercial sulfonylureas and their classification**


**First generation sulfonylureas**



Tolbutamide




Tolazamide




Chlorpropamide

**Second generation sulfonylureas**




Glipizide



Glibenclamide

**Third generation sulfonylureas**



Glimepiride

**USAGE**

The usual recommendation given by a doctor to patients is that Orinase is taken orally once daily within the morning. It generally will be divided into smaller parts especially if the patient experiences dyspepsia once taking the medication.<sup>(18)</sup> The dose is closely tied to medical condition and response to treatment of the patient. it's a standard technique to begin off with a coffee dose and begin increasing it over time to envision

if the patient laid low with any symptoms. Also, remember that particularly first-generation medication have interactions with alternative medication.<sup>(19)</sup>

## EFFECTS

Tolbutamide binds to the SUR1 – receptor, that may be a sub potassium-channel. This ultimately ends up in a change of the membrane. These ions initiate the merger of vesicles with the membrane. within those vesicles sits the endocrine waiting to be free from the cell.<sup>(20)</sup> when the merger it's free into the patient's metabolism, that ends up in lowered glucose levels. The management of high glucose levels helps stop urinary organ injury, blindness, nerve issues, loss of limbs, and sexual operate issues. correct medication against polygenic disease additionally might reduce the chance of a attack or stroke.<sup>(21)</sup>

## SIDE EFFECTS

1. Symptom (various symptoms caused by low glucose levels, e.g. 4. Drug interactions (especially first-generation drugs):
2. inflated symptom with alkaliser, insulin, salicylates, and sulphonamides<sup>(22)</sup>

## CONCLUSION

Type 2 DM is a metabolic disease that can be prevented through lifestyle modification, diet control, control of overweight and obesity. Education of the populace is still key to the control of this emerging epidemic.

## REFERENCES

1. Janbon M, Chaptal J, Vedel A, Schaap J, 1942. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP), Montpellier Med, 1942, 441: Pages-21-22.
2. Konno, Tortorelis, D G Fullerton, S A Samadi, Hettiarachchi J, Tazaki H, 2001. Diabetic medicine: a journal of the British Diabetic Association, 18(12): Pages-1010.
3. Hong Xun M, Wutong W, 2007. Anti-diabetic effect of an alpha-glucan from fruit body of maitake (*Grifola frondosa*) on KK-Ay mice, The Journal of pharmacy and pharmacology, 59(4): Pages-575–82. DOI: 10.1211/jpp.59.4.0013.
4. Kubo Aoki, Nanba, H, 1994. Anti-diabetic activity present in the fruit body of *Grifola frondosa* (Maitake). I, Biological & pharmaceutical bulletin, 17(8): Pages-1106–10. DOI: 10.1248/bpb.17.1106

5. Avinash Teli, Pawan Kumar, Akshi Denod, Md. Wasiullah, 2019. A prospective study on drug utilization and cost effectiveness of treatments in diabetes mellitus patients (inpatients setting) in teaching hospital of MMIMSR, Journal of Medical Pharmaceutical and Allied Sciences, V 8-I 4, 820, Pages-2276-2299. DOI - 10.22270/jmpas.v8i4.820
6. Manohar Talpur, NA Echard, BW Lieberman S, Preuss HG, 2002. Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice, Diabetes, obesity & metabolism, 4(1): Pages-43–8. DOI: 10.1046/j.1463-1326.2002.00180.x
7. Horio Ohtsuru, M Maitake, 2001. (*Grifola frondosa*) improve glucose tolerance of experimental diabetic rats, Journal of nutritional science and vitaminology, 47(1): Pages-57–63. DOI: 10.3177/jnsv.47.57
8. Zhang, Lin Z B, 2004. Hypoglycemic effect of *Ganoderma lucidum* polysaccharides, Acta pharmacologica Sinica, 25 (2): Pages-191–5.
9. Fortes Novaes, MR Recôva, VL Melo, 2009. Câncer colo retal Efeitos imunológicos, hematológicos e glicêmico do *Agaricus sylvaticus*, Experimental biology and medicine, (Maywood, N.J. 234 (1): Pages-53–62.
10. Kiho Sobue, S Ukai, 1994. Structural features and hypoglycemic activities of two polysaccharides from a hot-water extract of *Agrocybe cylindracea*, Carbohydrate research, 251: Pages-81–7. DOI: 10.1016/0008-6215(94)84277-9.
11. Kiho Yamane, A Hui J, Usui S, Ukai S, 1996. Polysaccharides in fungi. XXXVI. Hypoglycemic activity of a polysaccharide (CS-F30) from the cultural mycelium of *Cordyceps sinensis* and its effect on glucose metabolism in mouse liver, Biological & pharmaceutical bulletin, 19(2): Pages-294-6. DOI: 10.1248/bpb.19.294
12. A Bagust, S Beale, 2003. Deteriorating beta-cell function in type 2 diabetes: a long-term model, Q. J. Med, 96, Pages-281-288. Doi: 10.1093/qjmed/hcg040
13. A Ohneda, Y Maruhama, H Itabashi, Tohoku, 1978. Vascular complications and long-term administration of oral hypoglycemic agents in

- patients with diabetes mellitus, *J. Exp. Med.*, 124, Pages-205–222.
14. P M Dean, E K Matthews, 1968. Electrical Activity in Pancreatic Islet Cells, *Nature*, 219, Pages-389–390.
  15. P Rorsman, G Trube, 1985. Glucose dependent K<sup>+</sup>-channels in pancreatic beta-cells are regulated by intracellular ATP, *Eur. J. Physiol.* 405, Pages-305–309.
  16. Gurunani Shailju, Yeole Manjusha, Gholse Yogesh, Motghare Sonal, 2018. Natures approach to counteract diabetes, *Journal of Medical Pharmaceutical and Allied Sciences*. Volume 7-Issue 7, 761, Pages-1093-1099. DOI-10.22270/ujpr.v7i7.761.
  17. A E Spruce, N B Standen, P R, Stanfield, 1985. Studies of the unitary properties of adenosine-5'-triphosphate-regulated potassium channels of frog skeletal muscle, *Nature*, 316, Pages-736–738.
  18. D Stephan, M Winkler, P Kühner, U Russ, U Quast, 2006. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K (ATP) channels, *Diabetologia*, 49, Pages-2039–2048.
  19. N Inagaki, T Gono, N Namba, J Inazawa, G Gonzalez, L Aguilar-Bryan, S Seino, J Bryan, 1995. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor, *Science*, 270, Pages-1166–1170.
  20. E Markworth, C Schwanstecher, M Schwanstecher, 2000. ATP<sub>4</sub>- mediates closure of pancreatic beta-cell ATP-sensitive potassium channels by interaction with 1 of 4 identical sites, *Diabetes*, 49, Pages-1413–1418.
  21. C Ammala, A Moorhouse, F Gribble, R Ashfield, P Proks, P A Smith, H Sakura, B Coles, S J Ashcroft, F M Ashcroft, 1996. Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels. *Nature*, 379, Pages-545–548.